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CHAPTER 1:
Introduction

Overview
Diabetes mellitus affects a huge proportion of people; about 6% of the population
in the US had diabetes in 2007 (16). Diabetes promotes dyslipidemia, an imbalance in the
circulating levels of lipids and lipoproteins, and diabetes is one of the leading risk factors
for coronary artery and peripheral vascular diseases (11, 51, 52). There are two types of
diabetes; type 1 diabetes accounts for about 10% of diagnosed cases and type 2 accounts
for about 90% (11). Diabetic patients react differently to stents and there is a great need
to enhance the treatment. The goal of this project was, and continues to be, to create a
“diabetic” environment in which stents can be tested to characterize the potential of the
stent to continue with animal testing.

Cardiovascular Disease
Early in the progression of cardiovascular disease, endothelial dysfunction occurs.
The progression of endothelial dysfunction begins when the endothelial cells are
activated and express adhesion molecules such as intracellular adhesion molecule
(ICAM). From here the leukocytes stick to the adhesion molecules and migrate into the
vessel. The smooth muscle cells (SMCs) then migrate towards the intima and proliferate
and the beginning of a lesion is formed (32). Once the circulating lipoproteins bind, there
is a sustained inflammatory response and the lesion starts to grow and calcify; lipids
begin to accumulate and soon a significant lesion is formed. This build-up of plaque is
known as atherosclerosis and is illustrated in Figure 1.1. When this first occurs the vessel
will try to compensate by remodeling and expanding so the lumen remains the same size.
However, eventually the blood vessel narrows and blood flow is affected. There are two
2

main problems due to this progression. First, the narrowing of the vessel impedes the
blood flow and the tissue doesn’t receive the proper amount of oxygen and nutrients.
Second, the lesion can rupture and create a clot.

Figure 1.1- Progression of atherosclerosis in cardiovascular disease (1).

The current treatments for cardiovascular disease are lifestyle modifications,
drugs, angioplasty and/or stents, and bypass surgery. In angioplasty a balloon is used to
push the plaque against the vessel wall and often times a stent remains to prevent
restenosis. Stents are a huge area of research and are widely used in the clinic (cite).
Many new materials, such as biodegradable and drug eluting stents are currently being
researched (48). Biodegradable stents will provide the support long enough to prevent
restenosis, but degrade in time to allow for endothelialization- preventing late stent
thrombosis. Drug eluting stents are used to prevent the proliferation of cells, or
restenosis, but often times they prevent endothelialization and healing. Once a desired
stent has been developed, it must go through the FDA prior to market approval in the
U.S.
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In order to obtain FDA approval to market, much testing is required. Kristen
Cardinal’s Tissue Engineering Laboratory at California Polytechnic State University has
created an in vitro blood vessel mimic (BVM) to test stents and obtain data before the
stent is tested in animals. The BVM consists of an 8-roller pump, a reservoir for media
and a bioreactor for the engineered vessel. This set up can be seen in Figure 1.2. This is
a very valuable tool to save time, money and resources. Stents can be tested in a more
high throughput manner in vitro, and the stents that show the most potential can then be
tested further in animal models.

Figure 1.2- Blood vessel mimic as used to test stent characteristics.

Diabetes Mellitus
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There are two different types of diabetes; type 1 diabetes and type 2 diabetes.
Type 2 diabetes is often associated with obesity, lack of exercise, and unhealthy eating
choices (11). In this type of diabetes, insulin sensitivity is decreased, which ultimately
leads to inadequate release of insulin and β-cell failure. This can be apparent at either the
insulin receptor level or postreceptor signaling (11, 25). There are a few leading causes
of type 2 diabetes. The first is a decrease in the ability to increase the GLUT4 uptake of
glucose. This could be due to an increase in triglycerides (TG) in the muscle due to an
unhealthy diet causing hyperinsulemia (11). Initially, more glucose will be uptaken into
the skeletal muscle and this will increase lipogenesis and repress fatty acyl CoA
oxidation (11). Some of these byproducts, diacylglycerol and ceramide, will stimulate
signaling pathways as they accumulate, which disrupts signaling from the insulin receptor
(IR) and insulin receptor substrate (IRS) proteins (11). This will then create insulin
resistance in the skeletal muscle (11). The second cause of obesity-induced insulin
resistance is the decreased ability of insulin to repress hepatic glucose production (11).
The liver creates glucose through glycogenolysis and gluconeogenesis (11). Insulin
represses the enzymes in both of these pathways (11). The increase in visceral adipose
tissue can induce the effects of lipotoxicity by releasing cytokine tumor necrosis factor-α
(TNF-α), which can disrupt insulin signaling pathways (11). The third common reason
for insulin resistance is the inability of insulin to repress hormone-sensitive lipase (HSL)
or increase lipoprotein lipase (LPL) in adipose tissue (11). High HSL and low LPL are
commonly found in people with insulin resistance (11). This dyslipidemia is
characterized as hypertriglyceridemia with large TG-rich VDL particles that are produced
by the liver (11). These particles are digested efficiently creating small dense LDL
particles, known to be atherogenic (11). HDL, which protects against vascular disease,
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has also been shown to take on TG instead of cholesterol, which shortens the half-life of
HDL and decreases the HDL levels (11).
Type 1 diabetes is an autoimmune disease of the β-cells and is often onset in
childhood. β-cells produce insulin, and in Type I diabetics beta cells are destroyed, so
these patients are insulin dependent and need exogenous insulin to prevent ketosis. It is
believed that the initial stimulus can be due to a viral infection, which recruits leukocytes
to islets or dendritic cells in lymph that drain from islets and will present antigens to Tcells. This leads to insulitis, or inflammation of insulin producing cells, and ultimately βcell destruction. This disease can also be due to cytotoxicity, and it has been found that
NKp46, a receptor on CD8+ T-cells, is required for β-cell toxicity in animal models. The
inappropriate T-cell activation can also be caused by a couple of factors. First, glutamic
acid decarboxylase 65 (GAD65) is an enzyme found outside of cells; often times in type
1 diabetes the T-cells are reactive to GAD65. Second, the major histocompatibility
complex (MHC) genes may cause inappropriate T-cell activation. Third, there can be an
inappropriate expression of the insulin gene in the thymus, which is where the T-cells
mature. All of these can lead to type 1 diabetes.

Endothelial Cell Biology and Dysfunction
In the use of an in vitro BVM it is important to understand the structure and
function of the artery that is being mimicked. The blood vessel system can be subdivided
into three different components: arterial system, venous system and microcirculation
(11). There are a couple of key differences between each of these blood vessel systems.
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The arterial system distributes blood from the heart to the tissue, the venous system
delivers blood to the heart from the tissue, and the microcirculation system connects the
arterial and venous systems and allows for waste and nutrient exchange (11). The
capillaries of the microcirculation system consist of fenestrated and non-fenestrated
endothelial cells (ECs) as well as continuous and discontinuous ECs (5). Both the venous
and arterial systems are composed of only non-fenestrated, continuous endothelium (ECs
are tightly connected and surrounded by a continuous basement membrane) and the
arterial system also contains many tight junctions (5, 6). The ECs of the venous system
are phenotypically shorter and wider than those of the arterial system. The pressure in
the venous system is not as high as the arterial pressure and the venous system has valves
to prevent the back flow of blood. The venous system also has thinner walls. For the
reminder of this report, the arterial system will be the primary focus because the problem
lies in getting blood out to the body.
The artery is made of three layers: adventitia, media and intima, as illustrated in
Figure 1.3. The adventitia, the outermost layer, is composed of collagen, fibroblasts,
nerves (in the larger arteries) and vasovorum. The middle layer, the media, is composed
of smooth muscle cells (SMC) and elastin. The SMCs align perpendicular to blood flow
and therefore, wrap around the vessel. The inner layer, the intima, is composed of a
basement membrane and endothelium, which is composed of ECs. The ECs within the
artery align parallel to flow and are supported by the basement membrane. The ECs are
the blood contacting surface and tell the smooth muscle cells (SMCs) when to constrict
(4). The major function of the artery is to act as a conduit for blood, to provide an antithrombogenic lining, control blood cell trafficking, control permeability and help control
flow through dilation and constriction (4, 5).
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Figure 1.3 – The three arterial layers- adventitia, media and intima (1).

When using ECs in the laboratory or in tissue engineering, it is important to note
their source. ECs from capillaries in the skin, liver and brain all have very distinctive
properties and different surface protein expressions (15). The control of the plasticity of
the artery- and vein-specific properties is not completely understood. There are studies
supporting the hypothesis that these properties are epigenetically programmed before
blood flow. For example, the stimulation of arterial ECs with oxidized LDL had much
greater effects on the adhesion, proliferation and apoptosis than ECs from a human
saphenous vein (5). However, as in coronary artery bypass grafting, when veins are
grafted into the arterial system their walls thicken, permeability decreases, endothelial
nitric oxide synthase (eNOS) increases and thrombomodulin decreases (6). This lends
support to the hypothesis that structure and function are controlled by the
microenvironment. It is likely that the EC phenotype is controlled by both the
microenvironment and epigenetics. Input from the microenvironment can be attributed to
8

shear stress, growth factors, cytokines, chemokines, hormones, nitric oxide, oxygen and
reactive oxygen species (5). The phenotype of ECs can be determined or measured
through cell shape, protein expression, migration, proliferation, apoptosis, vasomotor
tone, hemostatic balance, release of inflammatory mediators, and leukocyte adhesion (5).
Endothelial cells are very important in the regulation of blood flow. This is
controlled by initiating/modulating an inflammatory response, activating leukocyte
trafficking, vasomotion and coagulation (33, 36). ECs express receptors for mediators on
their surface and they can release biologically active mediators such as cytokines and
hematopoietic growth factors (36). They produce and release nitric oxide (NO) and
prostacyclin (PGI2) both known vasodilators; as well as vasoconstrictors such as
endothelin, platelet –activating factor (PAF), and angiotensin II (13, 15, 25). These
compounds are regulated at the gene level; they are not present in the cell until a receptor
causes gene transcription (15). The endothelium in arteries is not highly permeable due to
the tight junctions (5). The endothelium can induce permeability when inflamed by the
formation of intracellular gaps. The formation of gaps can be enhanced by histamine,
serotonin, bradykinin and VEGF (5).
Leukocyte trafficking is accomplished through a multi-step process including
attachment, rolling arrest and transmigration (5). After the initial attachment, the
leukocyte interacts with endothelial E- and P-selectin to mediate the rolling (5). Next the
leukocyte integrins interact with ICAM-1 and vascular cell adhesion molecule (VCAM)1 (5). Finally, transmigration is mediated through the use of CD99, PECAM-1 (CD31)
and junctional adhesion molecule-1 (5). E- and P-selectin are not expressed in quiescent
ECs (5). ICAM-1 and VCAM-1 are expressed in areas that are predisposed to
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atherosclerosis, however they can be induced by activation agonists such as
lipopolysaccharide or tumor necrosis factor (TNF)-α (5). A study on mice showed that
TNF-α can upregulate ICAM-1, VCAM-1, E-selectin and P-selectin (5). The increase in
cell-adhesion molecules was correlated with increased adhesion of leukocytes (5).
Vasomotion is imperative in vessels. Healthy ECs release NO. NO diffuses to
the SMCs to control vasomotion. NO is also active in the inhibition of platelet activation,
prevention of SMC proliferation, monocyte adhesion, platelet aggregation and EC
apoptosis. NO release is regulated by physical activity, shear stress and hormones. PGI2
is also found in the endothelium and helps to inhibit platelet aggregation and prevent
proliferation of vascular smooth muscle cells (13). Endothelium-derived hyperpolarizing
factor (EDHF) is another important vasodilator; even when other factors are inhibited,
this can persist. Endothelin (ET)-1, produced by ECs, causes vasodilation at lower
concentrations and vasocontraction at higher concentrations (13). ET-1 enhances the
effects of other vasoconstrictors such as serotonin and norepinephrine. After
metabolization of ET, NO is helpful to restore the normal vasotone (13). Acetylcholine,
histamine and serotonin activate a receptor on SMCs and platetlets to counteract the
effects of NO and PGI2 (13). Angiotensin II is also important for vasoconstriction. It
helps maintain vascular tone, tissue formation and structure. Angiotensin-converting
enzyme (ACE), which converts angiotensin I to angiotensin II, is involved in the
breakdown of the stimulus bradykinin, needed for NO and PGI2 release (13).
ECs are imperative to maintain blood in a fluid state, they protect the circulating
blood from being exposed to prothrombotic subendothelial material (21). ECs release
several important mediators to prevent platelet activation, adhesion and aggregation (21).
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For anti-coagulation purposes, ECs in arteries express thrombomodulin, endothelial
protein C receptor (EPCR), tissue-type plasminogen activator (t-PA), ecto-ADPase,
prostacyclin, and NO (5). Vasodilators, PGI2 and NO, help to prevent platelet adherence
to the endothelium. NO has also been shown to limit the adhesion of monocytes,
preventing the build up of atherosclerotic plaque. NO and PGI2 are enhanced by
thrombin, bradykinin, serotonin, PDGF and IL-1 (13). For procoagulation, ECs express
tissue factor, plasminogen activator inhibitor (PAI)-1, von Willebrand factor (vWF),
cellular adhesion molecules, and protease activated receptors (5). Angiotensin II upregulates the expression of adhesion molecules causing circulating monocytes to adhere
to the endothelial surface. It also leads to platelet aggregation, thrombosis and migration
and growth of SMCs. In healthy ECs, angiotensin II is inhibited due to the presence of
NO, so the vessel wall is normally in a state of quiescence.
The balance between damage and repair of the vessel is imperative for proper EC
function (14). The damage process is not only dependent on the migration and
proliferation of mature ECs, but also on endothelial progenitor cells (EPCs). There are
three main cell types that contribute to vascular homeostasis. Endothelial colony forming
cells (ECFC) are highly proliferative and originate in the bone marrow (47). ECFC can
produce endothelial progeny, form endothelial tubes in vitro and contribute to neovascularization as well as re-endothelialization (47). The second type is circulating
angiogenic cells (CAC). CACs originate from the monocyte-macrophage lineage and are
involved in the uptake of acetylated low-density lipoprotein (LDL) (47). CACs produce
angiogenic cytokines that contribute to vascular homeostasis (47). The third type is
colony-forming units (CFU) composed of myeloid progenitor cells, monocytes and T
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lymphocytes. CFUs are often used as a biomarker for cardiovascular disease as they
have a high correlation with endothelial dysfunction.
There are many factors that can lead to systemic changes of the cardiovascular
system including hypertension, hyperglycemia and hyperlipidemia. These cause
disturbed flow, activation/dysfunction of ECs and ultimately inflammation, increased
oxidative stress, reduced NO bioavailability and monocyte extravasation (6). Impaired
NO production in conjunction with excessive oxidative stress causes a decline in NO
bioavailability leading to EC apoptosis (47). EC dysfunction impairs the vasomotion
and causes procoagulation, oxidative stress and inflammation and further progression to
atherosclerosis and diabetic complications.

Endothelial Cell Dysfunction in Diabetics
There are a couple of pathways that lead to endothelial cell dysfunction and
complications. The first is polyol-sorbitol; it leads to an increase in oxidant stress. The
second, hexosamine leads to an increase in transcription of proinflammatory cytokines.
The third, advanced glycation end product (AGE) decreases protease degradation of
collagen, creating a stiffer vascular wall and increasing proinflammatory cytokine
expression and PKC activation. AGE then binds with its cellular receptor leading to the
release of growth factors and activation of inflammatory pathways (13). AGE begins due
to chronic hyperglycemia and decreases NO delivery to SMCs. This can then lead to
atherosclerosis. AGE has been found to accumulate more quickly than normal in patients
with diabetes (51). The fourth pathway is direct activation of protein kinase C (PKC),
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which leads to an increase in inflammation and oxidant stress. PKC is activated by an
increase in diacylglycerol levels due to hyperglycemia. PKC then stimulates the NADPH
oxidase enzyme leading to superoxide production and oxidative stress (13). In an effort
to account for all of the different pathways involved in diabetes the following hypothesis
has been developed: there is an increase of superoxide production in ECs, which activate
the main pathways such as PKC and AGE to lead to EC dysfunction and atherosclerosis
(13). This hypothesis implies that EC dysfunction in diabetic patients is complex and
begins with an increase in oxygen free radicals and a decrease in NO bioavailability.
This is followed by inflammation and eventually atherosclerosis.
EC dysfunction is characterized by a decrease in vasodilation. In diabetic
patients, it has been found that there is a decrease in the formation of the vasodilator,
PGI2 (13). This occurs before any changes in the vessel structure, but can increase blood
pressure. NO is also decreased in active ECs. Oxygen-derived free radicals lead to an
increase in the degradation of NO by NADPH oxidase (13). Diabetes also leads to the
impairment of EDHF-dependent vasodilation (13). ET-1 is often found to be increased in
diabetic patients. It has been shown that ET-1 levels correspond to the number of
vascular complications in diabetic patients with clinical angiopathy (13).
EC dysfunction in diabetic patients is characterized by procoagulation; platelets
adhere to the ECs and aggregate. Most coronary events that occur are due to less than 1/3
narrowing of the vessel. ECs in regions of arteries with disturbed flow are primed for
activation by having increased levels of nuclear factor κB (NF-κB) in their cytoplasm
that can be translocated to the nucleus to increase the expression of procoagulants (5).
AGE’s receptor RAGE, can be activated by NF-κB leading to the expression of VCAM
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and ICAM (51). Diabetic patients express a number of coagulation factors that can lead
to increased levels of fibrinogen and thrombosis (13). There often is a defective response
to PGI2 and NO. With EC dysfunction, when platelets adhere to the vascular wall they
cause vasocontraction, and proliferation and migration of SMCs. The decrease in NO
along with the increase in various growth factors leads to proliferation.
EC dysfunction is also characterized by an increase in oxidative stress. This is
caused by the production of ROS as well as AGE/RAGE. The reaction of AGE and
RAGE can lead to a positive feed-back loop. AGE and RAGE induce the production of
reactive oxygen species (ROS), which leads to NF-κB and further production of ROS and
then more AGE products. This leads an the increase in O2 and oxidative stress in diabetic
vessels as well as a decrease in the bioavailability of NO (51).
EC dysfunction is associated with inflammation as well as atherosclerosis. EC
dysfunction can be used as a predictor of cardiovascular events (51). Activated ECs
increase leukocyte trafficking. Activated ECs release cytokines, this leads to the
accumulation of T cells and foam cells that perpetuate inflammation, lipid accumulation
and SMC activity. Some studies have shown that EPC numbers and function in diabetic
patients with cardiovascular risk factors are decreased (21). These EPCs are imperative
for endothelial repair and function. In summary, EC dysfunction is characterized by
procoagulation, an increase in oxidative stress, increase in oxidative stress, increase in
atherosclerosis and a decrease in vasodilation.

Implications of Endothelial Cell Dysfunction in Diabetic Patients
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EC dysfunction is not always associated with diabetes. EC dysfunction is
associated with atherosclerosis and cardiovascular disease, but one does not have to be
diabetic to express these cardiovascular risk factors (21). There are many conditions
predisposing of atherosclerosis and these include dyslipidemia, hypertension and
diabetes. Diabetes, therefore, is a risk factor for atherosclerosis and EC dysfunction (33).
Also, diabetic patients often have dyslipidemia and hypertension, both risk factors for
atherosclerosis. Therefore, a diabetic patient is at much greater risk of developing
atheroscerosis than a healthy individual because they often times have more risk factors.
Diabetic patients also have high glucose levels if they are not able to carefully control
their blood sugar levels (13). This increase in glucose level increases the superoxide
generation and disturbs proliferation; endogenous antioxidant enzymes are then overexpressed and there is an increase in free radicals and a decrease in NO (13). A decrease
in NO and increase in free radicals are both associated with EC dysfunction. Diabetes
and EC dysfunction are closely tied together, however, they are not mutually exclusive.
For the purpose of this project, EC dysfunction in diabetic patients will be the main
focus.
There are many complications associated with diabetes and EC dysfunction. One
complication is retinopathies, a major cause of blindness. There are non-proliferative as
well as proliferative retinopathies. In non-proliferative retinopathy microaneurisms occur
in the capillaries and block blood supply in the retina. As this becomes more severe,
proliferative retinopathy develops. Proliferative retinopathy is characterized by the
growth of new vessels in the retina. These vessels are very fragile and can leak blood
causing vision blindness or vision loss. Often times the pressure can be relieved before
causing blindness (3). Diabetic retinopathy is caused by a high intracellular glucose
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concentration in retinal ECs and pericytes due to hyperglycemia causing endothelial cell
dysfunction (11). Diabetes can cause peripheral nerve damage due to a diminished blood
supply to nerves. Diabetes can also lead to reduced renal function, chronic ulcerations,
and atherosclerosis.
Atherosclerosis is almost always present in diabetic patients after 5-10 years (13).
In diabetic patients, atherosclerosis tends to develop earlier than in non-diabetic patients.
Atherosclerosis can lead to myocardial infarction and stroke. LDL accumulates in the
intima of the artery and activates the endothelial cells to express adhesion molecules.
These molecules then adhere to monocytes and leukocytes, which migrate into the intima
(24). The monocyte derived macrophages upregulate scavenger receptors (SR) and tolllike receptors (TLR), which initiate signaling cascades and release cytokines, proteases
and vasoactive molecules leading to further inflammation and atherosclerotic build up.
Pro-inflammatory cytokines, proteases and coagulation factors produced by macrophages
as well as T cells can lead to degradation of the plaque and thrombosis. T cells in the
lesion lead to a Th1 response that is involved with IFN-γ and TNF, both of which have
been shown to promote atherosclerosis. The atherosclerotic progression can be seen in
Figure 1.4 (24). Anti-inflammatory cytokines, regulatory T cells and protective
antibodies can help to prevent atherosclerosis.
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Fig 1.4- Atherosclerosis pathway leading to thrombosis and blockage of blood flow (24).
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Inflammation is an important factor contributing to atherosclerosis (51). Local
inflammation can lead to plaque instability and ultimately thrombosis. Macrophages
release cytokines to recruit leukocytes and increase the presence of ICAM on the cell
surface as well as the production of NO. NO leads to vasodilation and an increase in
flow and leukocyte delivery, the leukocytes will adhere to adhesion molecules. The
circulating monocytes and leukocytes are then brought into the tissue leading to
inflammation. Inflammation is also accompanied by decreased bioavailability of NO
(51). The inflammation pathway can be seen in Figure 1.5.

18

Figure 1.5- Inflammation pathway contributing to atherosclerosis.
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Both atherosclerosis and inflammation are present in EC dysfunction and lead to
thrombosis and/or the prevent
prevention normal blood flow. Associated with these are all of the
complications found in diabetes.

Blood Composition
Blood composition is also important to understand in normal and diabetic
patients. Normal blood composition consists of low
low-density
density lipoprotein (LDL)
cholesterol < 100 mg/dL, high
high-density
density lipoprotein (HDL) cholesterol > 40 mg/dL and
total cholesterol
lesterol < 200 mg/dL (2, 31). These values can be seen in Table 1. HDL is an
important antioxidant and has anti
anti-inflammatory properties (10).. HDL plays a role in
transporting cholesterol from peripheral cells to the liver to be metabolized and excreted
(10).. Normal triglyceride llevels are considered < 150 mg/dL (31).
Table 1- LDL, HDL and total cholesterol levels as given by the National Institutes of Health.
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Diabetic Blood Composition
Research indicates that dyslipidemia and elevated LDL cholesterol is a major
cause of cardiovascular disease (10, 31, 41). These are associated with diabetic
complications including nephropathy, retinopathy and neuropathy and high triglycerides
(2, 31). High LDL is considered to be 160mg/dL, low HDL is considered to be < 40
mg/dL, high total cholesterol is considered to be > 240 mg/dL and high triglycerides are
considered to be > 200 mg/dL (2, 31). Once LDL levels are > 160 mg/dL
pharmacological therapy is recommended (2).
Dyslipidemia, which is characterized by hypercholesterolemia,
hypertriglyceridemia and low HDL, is very prevalent in those with type II diabetes (31).
The decrease in HDL levels are related to elevated plasma triglycerides (10). It has also
been found that type II diabetic patients who are obese have an even greater decrease in
HDL levels than non-obese diabetic patients (10). Type 1 diabetic patients also often
have dyslipidemia (31). A study was done that showed type 1 diabetic patients were
found to have high total cholesterol and LDL, but HDL and triglycerides were found to
be within a normal range (31). Glycemic control has been found to have a strong effect
on total cholesterol, LDL and triglyceride concentrations (41).

Stents in Diabetic Population
There are many differences in EC function between healthy patients and diabetic
patients so it is not unusual that diabetic patients might react differently to stents. And
diabetic patients are often times the people who are in need of stents, as diabetes is
associated with cardiovascular disease. 1.5 million revascularization procedures are
performed each year in the United States (20). About 25% of patients that undergo
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percutaneous coronary intervention have diabetes (52). Diabetic patients have been
shown to react differently than non-diabetic patients to implanted stents, often having an
increase in restenosis, which is defined as > 50% diameter stenosis (52). Diabetic
patients also typically have smaller coronary arteries to begin with, which could be partly
to blame for the higher restenosis rate (37). In a study done testing multivessel stenting
in diabetic patients it was found that there was a lower one-year survival in diabetic
patients that were treated with either oral antigens or insulin compared with non-diabetic
patients; about 85% in diabetic patients that were treated with oral antigens vs. 86% in
diabetic patients who were treated in insulin, compared to 95% in non-diabetic patients
(37). Diabetic patients also had an increase in target lesion revascularization (TLR) (37).
Fig. 1.6 shows the survival curve of diabetic patients treated with insulin, diabetic
patients treated with an oral agent and non-diabetic patients. An event-free survival was
considered to be freedom from death, Q-wave myocardial infarction (QMI) and TLR.
Those treated with insulin showed a trend towards an even higher revascularization rate
and lower one-year survival rate (37). The decreased performance in diabetic patients
may be due to new lesions or untreated previous lesions or a decrease in the
revascularization due to diseased coronary arteries (37).
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Figure 1.6- Survival curve after multivessel stenting
tenting illustrating that diabetic patients have a
decreased rate of event
event-free survival after multivessel stenting (37).

Another study evaluated patients from 16 interventional trials to determine which
factors might be most closely related to diabetic restenosis (49).. In this study all baremetal stents were used. Restenosis was found to increase after 6 months in diabetics
(31.1%) as compared to non
non-diabetics
diabetics (20.6%, P< 0.001). The predictors of restenosis
were determined to be vessel reference diameter, stented length of vessel and reduced
BMI (49).. The main determinant was found to be vessel reference diameter with an
increase of 6%, 9% and 13% above non
non-diabetic restinosis rates for large-,
large medium-, and
small-sized
sized vessels, respectively (49).
The SYNTAX (SYNergy Between PCI With TAXus and Cardia Surgery) study
compared coronary artery bypass graft surgery (CABG) and the TAXUS Express
paclitaxel-eluting
eluting stent (PES) in non
non-diabetic
diabetic and diabetic patients with complex left
main and/or 3-vessel
vessel disease (9).. Revascularization in the PES group was lower among
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the diabetic patients (49.1%) as compared to the non-diabetic patients (59.3%, P =
0.007), however, no statistical significance was found between the revascularization rate
of diabetic and non-diabetic patients treated with CABG (9). Major adverse cardiac and
cerebrovascular events (MACCE) was defined as including death, cerebrovascular
accident (CVA) and repeat revascularization. In one-year clinical results, MACCE was
significantly higher in diabetic patients after PES treatment compared with non-diabetic
patients (9). In patients who had medically treated diabetes, PES treatment was a
predictor for repeat revascularization but not death, CVS or MI (9). The differences in
diabetic patients may be due to inflammation, atherosclerosis or lesion complexity (9).
Another study looked to compare two different types of drug-eluting stents (19) in
diabetic patients, paclitaxel-eluting stents (PES) and sirolimus-eluting stents (37, 50). It
was found that thrombosis rates were higher in both stents among insulin-treated diabetic
patients compared to non-insulin treated patients (PES = 2.1% vs. SES = 2.8%, P = 0.74)
(50). The insulin-treated diabetic patients had higher rates of stent thrombosis compared
with the non-insulin treated patients (2.5% vs. 0.6%, P = 0.005) (50). Although, they did
not find a statistical difference between the two different types of stents, they did find that
insulin-treated diabetic patients are at a higher risk for thrombosis.
In patients with diabetes the prevalence of left main artery lesions, multivessel
disease and CAD are increased (20). Many studies support the finding that diabetic
patients are more likely to suffer restenosis, death or thrombotic complications compared
to non-diabetic patients (9, 20, 26, 37, 49, 52). There are several physiological reasons
that diabetic patients may fare worse. Platelets are more likely to aggregate and there can
be the development of hypertension, EC dysfunction, accelerated atherogenesis and
thrombosis (20, 26). Often times diabetic patients are found to have a smaller vessel
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diameter and larger vessel occlusion (20). Normally, bypass channels can form to pass
an obstruction, however, in diabetic patients there is an impaired ability to form coronary
collaterals (20). Diabetic patients are also less likely to undergo remodeling of their
coronary arteries to help compensate for an atherosclerotic build up and maintain proper
blood flow (20). Diabetes has a great effect on the success of a stent; the creation of a
diabetic environment to test a stent would be beneficial to delve into what characteristics
might reduce the rates of restenosis and thrombosis in diabetic patients.

Diabetic Models
Due to the somewhat distinct physiology of a subject with diabetes, diabetic
models are used to test stents before they proceed into a patient population. Diabetic
models help obtain important data to characterize which stents have potential in the
clinic. Diabetic animal models are necessary before stents can ultimately make it to the
clinic, but the more data that can be obtained from physiologic bench top tests the better.
There are currently many diabetic animal models, however, there are also additional
challenges and costs associated with using animal models as opposed to further benchtop
testing.
Three commonly used mice models are db/db, Akita and streptozotocin (STZ)
induced C57BL/6J. db/db mice are genetically diabetic, they possess a genetic mutation
of the leptin receptor and represent a model of type 2 diabetes through the presence of
hyperglycemia, obesity, and hyperinsulemia. Heterozygous Akita male mice represent
type 1 diabetes through a mutation in the insulin II gene leading to hypoinsulinemia and
eventually hyperglycemia (39). Akita mice are very expensive and many of the offspring
are not usable; they must be crossed with C57BL/6J mice and homozygous offspring die
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in 12 weeks and only heterozygous males can be used (39). STZ and alloxan are
mediated by reactive oxygen species; they can both be injected into animals to kill βcells, therefore rendering them unable to produce insulin, mimicking type 1 diabetes (39).
(39). To create C57BL/6J diabetic mice, injections must be given for 5 days and then
there is a 4 week latency period at which point some mice still do not portray a diabetic
model. This process requires extra time and resources (39).
Non-obese diabetic (NOD) mice are commonly used to study type 1 diabetes.
They spontaneously developed and display characteristics of hypercholesteremia and
hyperglycemia. In comparisons to humans, however, NOD mice are more often found in
females and are more susceptible to other autoimmune diseases. There are also some rats
that spontaneously develop type 1 diabetes such as Biobreeding rats, DP-BB rats,
Komeda Diabetes Prone rats, LEW.1AR1 rats and LEW.1WR1 rats (35, 50).
Rabbits are also commonly used to study diabetes. A diabetic model can be
created with an alloxan injection in New Zealand White rabbits (18). Beagle dogs have
also been used to induce diabetes with STZ, this occurs in ten days post injection (7).
Diabetic porcine models have been created with STZ in Chinese Guizhou minipigs (52).
Rhesus monkey can also be used to study type 1 diabetes through STZ treatment (42).
Total pancreatectomy is often used to induce diabetes in animal models (42). In rhesus
monkeys, 90% of the pancreas must be removed to cause diabetes leading to much
greater complexity and a 7-10 day recovery period (42). This surgery requires about 2-3
hours and requires a professional anesthesiologist to monitor the animal (42). The
postoperative procedures are very similar to that of a human (42). The use of a partial
pancreatectomy and STZ together lead to a diabetic model after six months in rhesus
monkeys (42).
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Much time and effort goes in to creating animal models that can mimic diseases.
While this is an imperative step, as animal testing creates a more physiologic
environment than benchtop tests, more testing can be done to improve data and find the
best candidate to pursue further testing. The use of animals for preclinical testing
requires more time, money and resources; more expertise and training is needed to
properly care for the animals as well as perform surgeries. All animal care must follow
proper protocol and procedures in accordance with specific guidelines. The use of a
“diabetic” BVM could potentially help to enhance this process by being used as a
preclinical test before stents are put into animal models to find the most promising stents.
With a “diabetic” environment the affect of diabetes on stents can be looked at more
closely and a stent can be designed with a higher success rate in diabetic patients.

Summary and Goals of this Project
The BVM has been created as an in vitro testing environment. It is beneficial to
get preliminary data regarding stent performance before animal testing is done. The
current BVM is designed to be as physiological as possible, although at best it represents
a “healthy” vessel environment. With the population of diabetics who end up with
cardiovascular disease and due to their varying blood composition as well as the fact that
they do not react the same to stents as non-diabetic patients, there is a need for a
“diabetic” testing environment to be created.
ECs are normally in a quiescent state; they are imperative for coagulation,
leukocyte trafficking and vasomotion. When ECs are activated as in diabetes, the
balance is thrown off, the ECs become procoagulant, lose vaso control and this
eventually leads to inflammation and atherosclerosis. EC activation has also been found
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to be correlated with ICAM-1 expression. ICAM-1 catches circulating monocytes and
leukocytes and brings them into the tissue leading to plaque build up. ICAM-1 has been
shown to be a marker present in patients with diabetes.
The broader goal of the BVM lab is to create a diabetic environment in the BVM
in which to test stents. In order to facilitate this goal, the aim of this project was to create
a protocol to test for the presence of ICAM-1, through immunohistochemistry. This
protocol will be obtained by testing human tonsil tissue, which is known to express
ICAM-1. Once this protocol can positively identify ICAM-1 using tonsil tissue, it will be
tested on HUVECs that have been cultured in the BVM on an ePTFE scaffold.
Eventually, different stimuli will be added to the media to up-regulate ICAM-1 leading to
a “diabetic” environment in which stents can be tested. This will be beneficial for
companies to have additional preliminary benchtop tests to perform on a “diabetic” blood
vessel mimic. It will save time, money and resources.
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CHAPTER 2:
ICAM-1
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Introduction
Coronary artery disease is a significant factor in the death of diabetic patients
(13). Since diabetic patients react differently to stents than non-diabetic patients, it
would be beneficial to have a “diabetic” environment with which to test stents. For the
purpose of this research a diabetic environment has been simply defined as an
environment in which ICAM-1 is upregulated. The first step in creating a diabetic
environment is to be able to test if ICAM-1 is in fact present. To do so a protocol to test
for ICAM-1 must be created. Once a working protocol exists, different methods can be
investigated to upregulate ICAM-1 and tested using the protocol to see if ICAM-1 is
upregulated.
ICAM-1 functions in the movement of leukocytes into tissues (25). ICAM-1 is
only synthesized upon activation and participates in leukocyte endothelial cell adhesion
in chronic inflammation (25). When there is no inflammation or infection both
leukocytes and endothelial cells are quiescent, however, if inflammatory signals are
released, ICAM-1 is produced and expressed on the cell surface. ICAM-1 mediates the
binding of leukocytes by interacting with carbohydrate ligands on leukocytes. Other
secreted activators cause changes in the shape of the leukocytes and activate leukocyte
integrins (such as αLβ2) causing a tighter bond between the leukocytes and ICAM-1.
This can be seen in figure 2.1. The leukocytes are then moved into the underlying tissue
leading to atherosclerotic plaque build-up and narrowing of the blood vessels (25).
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Figure 2.1- ICAM pathway illustrating ICAM
ICAM-1 expression and leukocyte adhesion (46).
(46)

Relevance of ICAM--1
In diabetes, the activation of ECs causes the upregulation of a couple of adhesion
molecules. ICAM-11 was chosen to be a marker for a diabetic environment because
research showed that ICAM
ICAM-1
1 is a powerful predictor of type 2 diabetes. A study done
d
in
2004, looked at the ability of elevated levels of ICAM
ICAM-1, e-selectin
selectin and VCAM-1
VCAM to
predict the development of type 2 diabetes (38). It was found that e-selectin
selectin and ICAM-1
ICAM
were predictors of type 2 diabetes even when corrected for BMI, family history of
diabetes, diet score and postmenopausal hormonal use. Along with these results, it was
also found that ICAM-11 was increased ten years prior to the onset of diabetes. It was
concluded that elevated plasma levels of ICAM
ICAM-1 and e-selectin
selectin were predictors of type 2
diabetes in initially healthy women (38).. Another study analyzed the relationship
between insulin resistance
tance and soluble adhesion molecule
molecules including ICAM-1,
ICAM VCAM-1
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and e-selectin (45). Soluble adhesion molecules are in the plasma and serve as markers
for adhesion molecules. In this research article, it was found that ICAM-1 and e-selectin
were inversely correlated with insulin sensitivity (45). This study, however, also found
that ICAM-1 was correlated with BMI and total body fat (45).
Yet another study looked at adhesion molecules in obese hypertensive men (19).
In this study, ICAM-1, VCAM-1 and e-selectin levels were found to be similar, not
related to hypertension, but rather due to obesity. Another study looked at ICAM-1,
VCAM-1 and selectins in people who were obese, hypertensive or type 1 diabetic (22).
There was an increase of ICAM-1, VCAM-1 and e-selectin in children and adults who
were type 1 diabetic, hypertensive or obese (22). In type 1 diabetic children, the levels of
ICAM-1 and e-selectin were increased; VCAM-1 and ICAM-1 were dependent upon type
1 diabetic children’s triglyceride levels (22). Children who were genetically predisposed
to diabetes had an increased level of ICAM-1. There was also an association of ICAM-1
with the risk of myocardial infarction (22). It was concluded that endothelial activation
was mostly found to be due to ICAM-1 and e-selectin (22).

ICAM-1 Analysis Techniques
The studies above all support the use of ICAM-1 as a predictor of diabetes, and
thus ICAM-1 was chosen as a marker for a diabetic environment in this project. There
are a couple of different ways that ICAM-1 can be measured- protein analysis, mRNA
analysis, immunohistochemistry and immunfluorescence. All of these techniques could
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possibly show if ICAM-1 is present or being upregulated. Certain procedures are better
for certain applications.
Protein expression of ICAM-1 can be done using an array biochip (14). This
method allows for many different proteins to be analyzed. Different DNA binding
sequences or antibodies can be placed onto the biochip to detect proteins in the solution.
In one study, researchers took blood samples and kept them at -70°C and then measured
for different adhesion molecules in the plasma (14). This is a good method to use when
there are cells in a solution that must be analyzed.
Flow cytometry is often used to count populations of interest. It can sort particles
based on their properties. Flow cytometry is often used in immunofluorescence.
Detectors can pick up the fluctuations in fluorescent emission peaks to determine the
amount of fluorescence present (27). In a published study, HUVECs were enzymatically
isolated and treated with different concentrations of D-glucose; the effect of D-glucose on
inflammation was analyzed. The HUVECs were first trypsinized and then put in a
blocking solution followed by a rinse in PBS (8). Next the cells were suspended in the
primary antibody and then the primary antibody was detected through the use of a
secondary antibody and the flow cytometer can measure the fluorescent intensity (8).
The researchers found that increased extracellular D-glucose did not cause ICAM-1
upregulation (8). Another study, that looked at the use of a mushroom to induce ICAM1, used flow cytometry to analyze the ICAM-1 protein on the cell surface, and
polymerase chain reaction (PCR) to analyze the mRNA level of ICAM-1 (29). To
measure the protein expression on the cell surface, the cells were stained with anti-human
ICAM-1 antibody conjugated with phycoerythrin. The cells were then analyzed with a
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flow cytometer and the data displayed the fluorescent intensities. In PCR, part of the
DNA will be amplified by going through denaturation and replication cycles;
complementary DNA is synthesized to allow for selective replication. mRNA was
analyzed to ensure that an increase in mRNA levels of ICAM-1 was correlated to an
increase in protein expression levels of ICAM-1.
Immunofluorescence is another very common technique to analyze the expression
of ICAM-1 levels. One study looked at the upregulation of ICAM-1 due to
lipopolysaccharide (LPS) (43). To use this method, samples were embed in tissuefreezing media and frozen at -70°C. A cryotome was used to cut sections and the
samples were then dried at room temperature for two hours. The sections were then
treated with a 30% methanol/ 70% acetone mixture (43). The sections were next fixed in
paraformaldehyde, washed in PBS (43). They were then incubated in 10% donkey serum
in PBS for 30 minutes to block nonspecific binding sites (43). Next was an incubation in
the primary antibody at a 1:200 dilution for one hour (43). Then the samples were
washed with PBS and incubated in Cy3-labeled donkey anti-rat IgG at a 1:250 dilution
for 45 minutes. The samples were then washed with PBS and counterstained with
fluorescein-labeled wheat germ agglutinin and bisbenzamide. Finally, the samples were
coverslipped (43). This method allowed researchers to see that there was an increase in
ICAM-1 expression due to LPS (43). In another study the effect of sustained hypoxia on
ICAM-1 was analyzed (12). To do so, rats were exposed to hypobaric hypoxia and then
the lung tissue was embedded. The protein level of ICAM-1 was found to increase
through immunofluorescent staining. Immunofluorescent staining is a very useful way to
determine if a certain protein is present. If the protein is present it will be tagged by the
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primary antibody and following reagents leading to the expression of fluorescence, which
can easily be seen.
Immunohistochemistry (IHC) is also frequently used to measure ICAM-1 levels.
To perform IHC, the samples are fixed, dehydrated and then embeded in paraffin wax
(8). Frozen tissue sections and tissue culture cells can also be used as samples (44). If the
samples are in paraffin wax, they can be sectioned and then stained with a primary
antibody, secondary antibody, AB enzyme reagent, followed by peroxidase substrate
(44). One study analyzed the simultaneous expression of ICAM-1, VCAM-1 and
vascular endothelial growth factor (VEGF) in diabetic fibrovascular membranes using
IHC (28). They used an anti-human ICAM-1 antibody. These samples were also
embedded in paraffin wax (28). The first step after sectioning the samples was to
rehydrate the samples in alcohols, incubate them in hydrogen peroxide, perform an
antigen retrieval step, incubate in a blocking solution, leave them overnight at 4°C with
the primary antibody, wash them in PBS, incubate with biotinylated secondary antibody
for 60 min, wash in PBS, and finally incubate in streptavidin horseradish peroxidase and
chromogen (28). This method allowed researchers to find coexpression of ICAM-1,
VCAM-1 and VEGF in most of the fibrovascular membranes they looked at. ICAM-1
was the most common, it was in eight of nine membranes (28). IHC is very similar to
immunofluoresence except instead of being tagged with fluorescence, a brown staining
will be shown if the protein being tagged is present.
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ICAM-1 Expression
The specific aim of this project is to create a protocol to determine if a “diabetic”
environment is created in the BVM to test stents by using ICAM-1 as a marker for
diabetes. In this project, IHC was the first method used. Tonsil tissue was used as a
positive control because research has shown that tonsil expresses adhesion molecules
including ICAM-1 (17). A lot of positive staining is typically seen in the high endothelial
venules (HEV) in the parafollicular regions, and lower border regions of the reticulated
epithelium. ICAM-1 can also be seen on epithelial cells of the crypts (40). The palatine
tonsil has openings called crypts that are lined with reticulated epithelium, which
contains epithelial cells, lymphocytes and endothelial cells- all of which stained positive
for ICAM-1 (30). Figure 2.2 below shows human palatine tonsils stained for ICAM-1;
the HEVs of the parafollicular region can be seen as PF, the cryptal epithelium is labeled
CE, and the follicular region (F) does not stain positive for ICAM-1 (40). Germinal
centers of the human tonsil also have a high uniform expression of ICAM-1 (23). The
protocol used in Figure 2.2 consisted of fixing the palatine tonsil in paraformaldehyde
and then frozen in liquid nitrogen (40). 30um sections were incubated at 4°C for 48
hours in the primary antibody (anti-ICAM-1). They were the incubated with goat-antimouse IgG, silver-enhanced, dehydrated, immersed in propylene oxide, infiltrated with
propylene oxide and resin and then embedded in TAAB-resin (40). Figure 2.2 shows
what might be expected to stain positive for ICAM-1.
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Figure 2.2- Immuno-electron-microscopic
staining of ICAM-1 on human palatine tonsils (40).

H&E
Since tonsil tissue is known to express ICAM
ICAM-1
1 it was used as a positive control
to create an ICAM-11 protocol. Before starting IHC, H&E staining was done to
characterizee the tissue. Hematoxylin will stain nuclei blue; the eosin stains cytoplasm
pink. The first H&E protocol can be seen below. It was verified that this was tonsil
tissue by looking at the H&E slides. A microtome was used to make sections of 6um.
Pants, closed toed shoes and gloves were worn at all times. All steps were performed in
the fume hood, and slides were allowed to dry for 48 hours before viewing in the
microscope.
Protocol #1: H&E Staining of human tonsil tissue. October 18, 2009.
Purpose: See the structure and morphology of the tonsil tissue.
Materials: Paraffin embedded tonsil tissue obtained in October, 2009.
Process:
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1) 3 minutes in xylene
2) 3 minutes in xylene
3) 3 minutes in xylene
4) 2 minutes in 100% EtOH
5) 2 minutes in 100% EtOH
6) 2 minutes in 95% EtOH
7) 1 minute air dry
8) 4 minutes in hematoxylin
9) 1 minute in distilled H2O
10) 30-45 seconds in clarifier
11) 1 minute in distilled H2O
12) I minute in bluing
13) 1 minute in distilled H2O
14) 1 minute in 95% EtOH
15) 1 minute 30 sconds in eosin
16) 1 minute in 100% EtOH
17) 1 minute in 100% EtOH
18) 1 minute in 100% EtOH
19) 3 minutes in xylene
20) 3 minutes in xylene
21) 3 minutes in xylene
This first protocol created tissue samples that were dark purple so the hematoxylin
time was decreased. The next protocol was changed from 4 minutes in hematoxylin to 3
minutes in hematoxylin. This was better, but still a little dark. H&E staining was done
one more time with 2:30 minutes in hematoxylin and the samples were much easier to
see. The last protocol with hematoxylin time at 2:30 minutes was accepted. Images of
the tonsil tissue at all of the different hematoxylin times can be seen below.
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Figure 2.3- Tonsil tissue in hematoxylin for 4 minutes

Figure 2.4- Tonsil tissue in hematoxylin for 3 minutes

Figure 2.5- Tonsil tissue in hematoxylin for 2:30 minutes

Final Protocol: H&E Staining of human tonsil tissue- Protocol Accepted. January 9,
2010.
Purpose: See the structure and morphology of the tonsil tissue.
Materials: Paraffin embedded tonsil tissue obtained in October, 2009.
Process:
1) 3 minutes in xylene
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2) 3 minutes in xylene
3) 3 minutes in xylene
4) 2 minutes in 100% EtOH
5) 2 minutes in 100% EtOH
6) 2 minutes in 95% EtOH
7) 1 minute air dry
8) 2:30 minutes in hematoxylin
9) 1 minute in distilled H2O
10) 30-45 seconds in clarifier
11) 1 minute in distilled H2O
12) I minute in bluing
13) 1 minute in distilled H2O
14) 1 minute in 95% EtOH
15) 1 minute 30 sconds in eosin
16) 1 minute in 100% EtOH
17) 1 minute in 100% EtOH
18) 1 minute in 100% EtOH
19) 3 minutes in xylene
20) 3 minutes in xylene
21) 3 minutes in xylene

Immunohistochemistry
Next an ICAM-1 IHC protocol was worked on. Anti-ICAM-1 antibody, catalog
number sc-107 was purchased from Santa Cruz Biotechnology along with mouse ABC
system sc-2017. The ABC system comes with suggested instructions ranging in times
and concentrations. Protocol #1 is shown below. Before the protocol is begun, the
samples are sectioned at 6um. Control slides were incubated in PBS while the
experimental slides were incubated with the primary antibody. A Tupperware was used
as a humidified chamber, to do so a paper towel was wetted and placed on the bottom of
the tupperware. The slides then sat on the paper towel. To aspirate off reagents, one
slide was aspirated, the new reagent was put on and then the next slide was aspirated and
then a new reagent put on. This continued until all the slides were incubating in the new
reagent and prevented the slides from drying out. For safety precautions closed toed
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shoes, long pants and gloves should be worn at all times. The AB enzyme reagent should
be mixed in the hood. All reagents must be made fresh and if extras are left, disposed of
in the waste container.
Protocol #1: Immunohistochemistry analysis of human tonsil tissue using ICAM-1
antibody to create a positive control. October 13, 2009.
Purpose: To stain human tonsil tissue for ICAM for a positive control.
Materials: Paraffin embedded tonsil tissue obtained in October, 2009. ICAM-1 antibody
from Santa Cruz Biotechnology. Mouse ABC kit. Control: 09-176-2
Process:
1) Mix PBS as per directions on the packet
one pouch PBS, pH 7.4 mixed with 1L distilled H2O
2) incubate slides with two changes of PBS for 5 minutes
3) Prepare primary antibody- 1µg/ml
•
•

Pipette 5 µl ICAM antibody
Pipette 0.995 ml blocking serum

4) incubate slides with primary antibody prepared above for 30 minutes
5) Wash with 3 changes of PBS for five minutes each
6) Prepare secondary antibody (green bottle) as follows
•
•
•

75µl normal blocking serum
5ml PBS
25µl secondary antibody stock

7) incubate with newly prepared secondary antibody for 30 minutes
8) Prepare antibody enzyme reagent in hood
•
•
•

50µl advin
50µl biotinylated HRP
2.5ml PBS

9) Wash with 3 changes of PBS for 5 minutes each
10) incubate sections with antibody enzyme reagent for 30 minutes
11) Wash with three changes of PBS for 5 minutes each
12) Prepare peroxidase substrate
•
•
•
•

1.6ml distilled H2O
5 drops 10x substrate buffer
1 drop 50x DAB chromogen
1 drop 50x peroxidase substrate

13) incubate peroxidase substrate for 5 minutes
14) Wash in distilled water for 5 minutes
15) incubate in 95% ethanol twice for ten seconds each
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16) incubate in 100% ethanol twice for ten seconds each
17) incubate in xylene three times for ten seconds each
18) Add 1-2 drops of mounting medium and cover.
19) Let dry for 48 hours
This protocol did not show any positive staining of ICAM-1, endogenous staining
were seen in the control and the experimental samples. The next time IHC was
attempted, the concentration of ICAM-1 antibody was changed from 1ug/ml to 3ug/ml.
This did not show any positive staining either. The ICAM-1 antibody was then increased
to 5ug/ml again resulting in no positive staining. The next protocol will be considered
protocol #2. This protocol kept the ICAM-1 antibody concentration at 5mg/ml but added
dehydration steps at the beginning, added the pap pen and added an hour incubation in
normal blocking serum. The pap pen creates a hydrophobic barrier so the solutions will
stay over the tissue section; the blocking serum will help to block endogenous staining.
Protocol #2: Immunohistochemistry analysis of human tonsil tissue using ICAM-1
antibody to create a positive control. February 20, 2010.
Purpose: To stain human tonsil tissue for ICAM for a positive control.
Materials: Paraffin embedded tonsil tissue obtained in October, 2009. ICAM-1 antibody
from Santa Cruz Biotechnology. Mouse ABC kit. Control: 09-18A, 09-184D
Process:
1) Mix PBS as per directions on the packet
One pouch PBS, pH 7.4 mixed with 1L distilled H2O
2) incubate slides with two changes of PBS for 5 minutes
3) Wash slides in xylene for 5 minutes
4) Wash slides in xylene for 5 minutes
5) Prepare blocking serum
•
•
•
•

75 µl normal blocking serum
5 ml PBS
Remove 0.990 ml to add to ICAM-1 antibody
Save some to incubate control slide in blocking serum

5) Wash slides in 100% ethanol for 1 minute
6) Wash slides in 100% ethanol for 1 minute
7) Wash slides in 95% ethanol for 1 minute
8) Remove slides, let them dry a little and add pap pen
9) incubate slides with blocking serum for 1 hour

42

•

Suction reagent after 1 hour, one slide at a time adding new reagent to each to
prevent drying out

10) Prepare primary antibody- 5 µg/ml 30-45 minutes into step 8
•
•

Pipette 25 µl ICAM antibody
Pipette 0.975 ml blocking serum

11) incubate slides with primary antibody prepared above for 30 minutes
12) Wash with 3 changes of PBS for five minutes each
13) Prepare secondary antibody (green bottle) as follows
•
•
•

75µl normal blocking serum
5ml PBS
25µl secondary antibody stock

14) incubate with newly prepared secondary antibody for 30 minutes
15) Prepare antibody enzyme reagent in hood
•
•
•

50µl advin
50µl biotinylated HRP
2.5ml PBS

16) Wash with 3 changes of PBS for 5 minutes each
17) incubate sections with antibody enzyme reagent for 30 minutes
18) Wash with three changes of PBS for 5 minutes each
19) Prepare peroxidase substrate
•
•
•
•

1.6ml distilled H2O
5 drops 10x substrate buffer
1 drop 50x DAB chromogen
1 drop 50x peroxidase substrate

20) incubate peroxidase substrate for 5 minutes
21) Wash in distilled water for 5 minutes
22) incubate in 95% ethanol twice for ten seconds each
23) incubate in 100% ethanol twice for ten seconds each
24) incubate in xylene three times for ten seconds each
25) Add 1-2 drops of mounting medium and cover.
26) Let dry for 48 hours
This protocol was not successful. The next IHC protocol removed the PBS step
before the slides were put into xylene for the first time, and added a hydrogen peroxide
step for five minutes after the pap pen was applied to the samples. This was not
successful. The next protocol was done with some of the samples in hydrogen peroxide
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and some without hydrogen peroxide. When the hydrogen peroxide is used, less
endogenous staining is seen in the tonsil tissue, however, there is still endogenous
staining in both the samples treated with ICAM-1 antibody and those without. IHC
images from this protocol can be seen in Figure 2.6 and 2.7. The tonsil tissue was
washed in PBS by putting them in dishes in some cases and pipetting PBS over the
samples in other times. Neither of these techniques made a difference. The next time
IHC was attempted, the hydrogen peroxide step was omitted and the samples were
incubated with the primary antibody overnight at 4°C instead of for 30 minutes at room
temperature. The samples were also incubated in the peroxidase substrate for ten
minutes, as opposed to five minutes. The controls were left in PBS overnight; still no
positive ICAM-1 staining was seen.

Figure 2.6- Tonsil tissue without hydrogen peroxide
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Figure 2.7- Tonsil tissue with hydrogen peroxide

The next trial included an antigen retrieval step, increased the dehydration steps,
and did not have a hydrogen peroxide step. Sometimes when samples are embedded in
paraffin wax, the wax can block the antigen from binding to the primary antibody; using
an antigen retrieval step can unmask the antigen. This heat treatment step was done by
incubating the samples in a 0.05% saponin solution. Again, no positive staining was
seen; both the control and the experimental slides showed brown staining. The next
protocol included the same antigen retrieval step with saponin, but also included a
hydrogen peroxide step. Again, no positive staining was found. For the next protocol the
hydrogen peroxide was found to have been expired so it was omitted and sodium citrate
was used for an antigen retrieval step. Sodium citrate was ordered from Santa Cruz
Biotechnology, sc-203383. This protocol will be considered protocol #3.
Protocol #3: Immunohistochemistry analysis of human tonsil tissue using ICAM-1
antibody to create a positive control. April 17, 2010.
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Purpose: To stain human tonsil tissue for ICAM for a positive control.
Materials: Paraffin embedded tonsil tissue obtained in October, 2009. ICAM-1 antibody
from Santa Cruz Biotechnology. Mouse ABC kit. Control: 09-180B, 09-183B
Process:
1) incubate slides in the oven for 10 minutes
2) Let slides cool for 5 minutes
3) Wash slides in xylene for 5 minutes
4) Mix PBS as per directions on the packet
One pouch PBS, pH 7.4 mixed with 1L distilled H2O
5) Wash slides in xylene for 5 minutes
6) Wash slides in xylene for 5 minutes
7) Wash slides in 100% ethanol for 10 minutes
8) Wash slides in 100% ethanol for 10 minutes
9) Wash slides in 95% ethanol for 10 minutes
10) Wash slides in 95% ethanol for 10 minutes
11) Heat 10mM sodium citrate buffer, pH 6.0
•

95°C

12) incubate slides in distilled water for 1 minute with stirring
13) incubate slides in 95°C sodium citrate buffer for 5 minutes
•

use incubator to keep sodium citrate hot

14) Heat new 10mM sodium citrate buffer for 5 minutes
15) incubate slides in 95°C sodium citrate buffer for 5 minutes
•

use incubator to keep sodium citrate hot

16) Allow slides to cool in sodium citrate buffer for 20 minutes
17) Wash in distilled H2O three times for 2 minutes each
18) Add pap pen to samples
19) Prepare blocking serum
•
•
•
•

75 µl normal blocking serum
5 ml PBS
Remove 0.975 ml to add to ICAM-1 antibody
Save some to incubate control slide in blocking serum

20) incubate slides with blocking serum for 1 hour
•

Suction reagent after 1 hour, one slide at a time adding new reagent to each to
prevent drying out

21) Prepare primary antibody- 5 µg/ml 30-45 minutes into step 8
•
•

Pipette 25 µl ICAM-1 antibody
Pipette 0.975 ml blocking serum
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22) incubate slides with primary antibody prepared above for 30 minutes at room
temperature
23) Wash with 3 changes of PBS for five minutes each
24) Prepare secondary antibody (green bottle) as follows
•
•
•

75µl normal blocking serum
5ml PBS
25µl secondary antibody stock

25) incubate with newly prepared secondary antibody for 30 minutes
26) Prepare antibody enzyme reagent in hood- must sit for 30 minutes
•
•
•

50µl advin
50µl biotinylated HRP
2.5ml PBS

27) Wash with 3 changes of PBS for 5 minutes each
28) incubate sections with antibody enzyme reagent for 30 minutes
29) Wash with three changes of PBS for 5 minutes each
30) Prepare peroxidase substrate
•
•
•
•

1.6ml distilled H2O
5 drops 10x substrate buffer
1 drop 50x DAB chromogen
1 drop 50x peroxidase substrate

31) incubate peroxidase substrate for 5 minutes
32) Wash in distilled water for 5 minutes
33) incubate in 95% ethanol twice for ten seconds each
34) incubate in 100% ethanol twice for ten seconds each
35) incubate in xylene three times for ten seconds each
36) Add 1-2 drops of mounting medium and cover
37) Let dry for 48 hours

In this protocol, the sodium citrate was heated in the microwave and then put into
the incubator to keep warm. However, the incubator only kept the sodium citrate at
80°C, which is much lower than the recommended 95°C. In the next try, sodium citrate
was used (still did not reach the desired temperature) and the blocking serum incubation
for one hour was omitted. In the next protocol the sodium citrate was heated in a beaker
(from VWR, which has a heat rating of 400°C) on a hot plate and the solution was kept at
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95°C. The hydrogen peroxide was also used. It was later found that the blocking serum
used in protocol #3 and the following protocols was mouse serum and should have been
goat serum. None of these protocols showed any positive ICAM-1 staining, there was a
lot of endogenous staining seen on all of the slides.

Immunofluorescence
Due to the high amount of endogenous staining seen, it was decided to switch to
immunofluorescence. Ultra cruz mounting medium (sc-24941), goat anti-mouse IgGFITC (sc-2010), and goat blocking serum (sc-2043) were ordered from Santa Cruz
Biotechnology. The initial immunofluorescence protocol will be considered protocol #1
and can be seen below. Tonsil tissue was still used for the positive control.
Protocol #1: Immunofluorescent analysis of human tonsil tissue using anti-ICAM-1
antibody to create a positive control. May 9, 2010.
Purpose: To stain human tonsil tissue for ICAM for a positive control.
Materials: Paraffin embedded tonsil tissue obtained in October, 2009. ICAM-1 antibody
from Santa Cruz Biotechnology. Goat anti-mouse IgG-FITC. Goat blocking serum.
Control: 09-180C, 09-184C.
Process:
1) incubate slides in the oven for 10 minutes
2) Let slides cool for 5 minutes
3) Wash slides in xylene for 5 minutes
4) Mix PBS as per directions on the packet
•

One pouch PBS, pH 7.4 mixed with 1L distilled H2O

5) Wash slides in xylene for 5 minutes
6) Wash slides in xylene for 5 minutes
7) Wash slides in 100% ethanol for 10 minutes
8) Heat 10mM sodium citrate buffer, pH 6.0 in a 1 L VWR beaker on a hot plate until it
boils
•

95°C

9) Wash slides in 100% ethanol for 10 minutes
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10) Wash slides in 95% ethanol for 10 minutes
11) Wash slides in 95% ethanol for 10 minutes
12) incubate slides in distilled water for 1 minute with stirring
13) incubate slides in 95°C sodium citrate buffer for 5 minutes
•
•

use hot plate to keep sodium citrate hot
put slide rack in 1 L VWR beaker

14) Top 10mM sodium citrate buffer to 500 ml in 1 L VWR beaker
15) incubate slides in 95°C sodium citrate buffer for 5 minutes
•

use hot plate to keep sodium citrate hot

16) Allow slides to cool in sodium citrate buffer for 20 minutes
17) Wash in distilled H2O three times for 2 minutes each
18) Prepare 10% normal blocking serum- goat
•
•
•

0.25 ml normal blocking serum (goat)
2.25 ml PBS
This can be replaced with bovine serum albumin

19) Add pap pen to samples
20) incubate in normal blocking serum for 20 minutes
21) Wash with PBS- 5 minutes
22) Prepare primary antibody
•
•
•
•

15 µl normal blocking serum
0.985 ml PBS
20 µl anti-ICAM antibody  1:50 dilution
can try 0.5- 5.0µg/ml

23) incubate slides with primary antibody for 1 hour
•

Suction reagent after 1 hour, one slide at a time adding new reagant to each to
prevent drying out

24) Wash with 3 changes of PBS for five minutes each
25) Prepare fluorochrome-conjugated secondary antibody
•
•
•
•
•

30 µl normal blocking serum
1.97 ml PBS
15 µl secondary antibody
Can try 1.0- 5.0µg/ml (this one is 3µg/ml)
Can mix normal blocking serum to be 1.5% (now) to 3%

26) incubate with newly prepared secondary antibody for 45 minutes
•

Must be in a dark chamber

27) Wash with 3 changes of PBS for 5 minutes each
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28) Mount coverslip with aqueous mounting medium or 90% glycerol in PBS

After protocol #1, background staining was seen in the control and experimental
slides. Images from protocol #1 can be seen in figure 2.8 and 2.9. In the next protocol,
the FITC concentration was adjusted from a 3mg/ml dilution to a 1ug/ml dilution (1:500).
It was also found that some of the beakers do not fit the slide racks- even beakers with the
same catalog number. From then on the beaker was tested with the slide rack to ensure
the slide rack will fit into the beaker before sodium citrate was added to the beaker and
heated. The next protocol diluted the FITC even more to a 1:1000 dilution. Still
background staining was seen, as shown in Figures 2.10 and 2.11. There is nothing
known in tonsil tissue that the secondary tissue should be binding too. Both tonsil tissue
and the reagents from Santa Cruz Biotechnology have been cited in research articles. To
test for background staining both a different species secondary antibody was tried and
culturing HUVECs as opposed to using tonsil tissue was tried. This resulted in
background staining still being seen. Since the background staining is seen with both
secondary antibodies, it is likely that the background staining could be due to the sample
rather than the reagents.
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Figure 2.8- Immunofluorescent image of control (w/o primary antibody)

Figure 2.9- Immunofluorescent image of experimental tissue, protocol #1

Figure 2.10- Immunofluorescent image of control (w/o primary antibody),
1:1000 FITC dilution

51

Figure 2.11- Immunofluorescent image of experimental tissue,
1:1000 FITC dilution

The immunofluorescent protocol on HUVECs can be seen below.
Protocol #2: Immunofluorescent analysis of HUVECS using anti-ICAM-1 antibody to
create a positive control. May 20, 2010.
Purpose: To stain human tonsil tissue for ICAM for a positive control.
Materials: HUVECs p9. ICAM-1 antibody from Santa Cruz Biotechnology. Goat antimouse IgG-FITC. Goat blocking serum. Dextran. Control: cultured in DMEM, not
dextran
Process:
1) Make dextran: 10%, 20%, 30% (and DMEM = control)
•
•
•
•

1ml = 1 gram
0.63 grams dextran: 9.37 ml DMEDM
1.4 grams dextran: 8.6 ml DMEM
1.75 grams dextran: 8.25 ml DMEM

2) Culture cells with dextran for 24 hours
3) Fix cells: 5 minutes in -10º C methanol, air dry
4) Wash cells in three changes of PBS
5) Mix PBS as per directions on the packet
•

One pouch PBS, pH 7.4 mixed with 1L distilled H2O

6) Prepare 10% normal blocking serum- goat
•
•
•

0.20 ml normal blocking serum (goat)
1.8 ml PBS
This can be replaced with bovine serum albumin

7) Incubate in normal blocking serum for 20 minutes
8) Wash with PBS- 5 minutes
9) Prepare primary antibody
•
•
•
•

15 µl normal blocking serum
0.985 ml PBS
20 µl anti-ICAM antibody  1:50 dilution
can try 0.5- 5.0µg/ml

10) Incubate slides with primary antibody for 1 hour
•

Suction reagant after 1 hour, one slide at a time adding new reagant to each to
prevent drying out
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11) Wash with 3 changes of PBS for five minutes each
12) Prepare fluorochrome-conjugated secondary antibody (recommend 1:500 dilution)
this is 1:1000 dilution
•
•
•
•
•

60 µl normal blocking serum
1.94 ml PBS
2 µl secondary antibody
Can try 1.0- 5.0µg/ml
Can mix normal blocking serum to be 1.5% to 3% (now)

13) Incubate with newly prepared secondary antibody for 45 minutes
•

Must be in a dark chamber

14) Wash with 3 changes of PBS for 5 minutes each
15) Mount coverslip with aqueous mounting medium or 90% glycerol in PBS.
When the HUVECs were imaged, it was found that there were no cells attached to
the four well plates. The most likely reason is due to the cells not properly being fixed.
The temperature of the methanol was not measured before it was put onto the cells,
however, the methanol was left in the freezer for 24 hours before being used. The
methanol must also be allowed some time to air dry without drying the cells out- this
could have needed to air dry for longer.
The immunofluorescent protocol used with the donkey anti-mouse IgG-FITC can
be seen below. There were some changes in this protocol compared to protocol #2. The
PBS wash after the incubation with the normal blocking serum was changed from 5
minutes to one minute. The control slides were incubated with a 10% normal blocking
serum in PBS instead of just PBS. After the incubation with FITC there were three PBS
washes added, then three five minute incubations and then three rinses before being
coverslipped.
Protocol #3: Immunofluorescent analysis of human tonsil tissue using anti-ICAM-1
antibody to create a positive control. May 22, 2010.
Purpose: To stain human tonsil tissue for ICAM-1 for a positive control.
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Materials: Paraffin embedded tonsil tissue obtained in October, 2009. HUVECS on
ePTFE embed in paraffin wax. ICAM-1 antibody from Santa Cruz Biotechnology.
Donkey anti-mouse IgG-FITC. Donkey blocking serum. Control: 09-178C
Process:
1) Incubate slides in the oven for 10 minutes
2) Let slides cool for 5 minutes
3) Wash slides in xylene for 5 minutes
4) Mix PBS as per directions on the packet
•

One pouch PBS, pH 7.4 mixed with 1L distilled H2O

5) Wash slides in xylene for 5 minutes
6) Wash slides in xylene for 5 minutes
7) Wash slides in 100% ethanol for 10 minutes
8) Heat 10mM sodium citrate buffer, pH 6.0 in a 1 L VWR beaker on a hot plate until it
boils
•

95°C

9) Wash slides in 100% ethanol for 10 minutes
10) Wash slides in 95% ethanol for 10 minutes
11) Wash slides in 95% ethanol for 10 minutes
12) Incubate slides in distilled water for 1 minute with stirring
13) Incubate slides in 95°C sodium citrate buffer for 5 minutes
•
•

use hot plate to keep sodium citrate hot
put slide rack in 1 L VWR beaker

14) Top 10mM sodium citrate buffer to 500 ml in 1 L VWR beaker
15) Incubate slides in 95°C sodium citrate buffer for 5 minutes
•

use hot plate to keep sodium citrate hot

16) Allow slides to cool in sodium citrate buffer for 20 minutes
17) Wash in distilled H2O three times for 2 minutes each
18) Prepare 10% normal blocking serum- donkey
•
•
•

0.20 ml normal blocking serum (donkey)
1.8 ml PBS
This can be replaced with bovine serum albumin

19) Add pap pen to samples
20) Incubate in normal blocking serum for 20 minutes
21) Wash with PBS- 5 minutes
22) Prepare primary antibody
•
•
•

15 µl normal blocking serum
0.985 ml PBS
20 µl anit-ICAM-1 antibody  1:50 dilution
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•

can try 0.5- 5.0µg/ml

23) Incubate slides with primary antibody for 1 hour
•

Suction reagant after 1 hour, one slide at a time adding new reagant to each to
prevent drying out

24) Wash with 3 changes of PBS for five minutes each
25) Prepare fluorochrome-conjugated secondary antibody (recommend 1:500 dilution)
this is 1:1000 dilution
•
•
•
•
•

60 µl normal blocking serum
1.94 ml PBS
2 µl secondary antibody
Can try 1.0- 5.0µg/ml
Can mix normal blocking serum to be 1.5% to 3% (now)

26) Incubate with newly prepared secondary antibody for 45 minutes
•

Must be in a dark chamber

27) Wash with 3 changes of PBS for 5 minutes each
28) Mount coverslip with aqueous mounting medium or 90% glycerol in PBS
During this protocol, the HUVECs on ePTFE all fell off of the slide during the
heat treatment step. To retry the HUVECs without the heat treatment step, protocol #3
was adhered to with the omittance of the heat treatment step. The tonsil tissue in
protocol#3 still showed background staining. It was found that the hydrophobic barrier
pen that is used to keep the reagents over the sample fluoresces. Vector Laboratories was
contacted and it was stated that the pen and its residue does fluoresce, however, this
should not affect the tissue samples. Images of this can be seen in figure 2.12. The
fluorescing of the tonsil tissue does not look like residue of the pen; it looks like circular
cells and the cells are fixed before they come into contact with the pen so their expression
will not be altered.
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Figure 2.12- Fluorescence of the hydrophobic barrier pen.

Summary
After protocol #3, due to the continuing result of non-specific staining, the tonsil
tissue was further analyzed to try to figure out why there is background staining. Even
using both IHC and immunofluorescence, background staining was seen. Concentrations
of reagents were changed, incubation times were changed, and secondary antibodies were
changed. None of these attempts lead to successful identification of ICAM-1 on the
tonsil tissue.
The tonsil tissue, received from Central Coast Pathology was most likely fixed in
formalin. The time that the samples are in formalin can greatly increase the background
staining. Since the tonsil tissue was received already fixed, it is unknown how long they
were in formalin. Therefore, further methods need to be analyzed to create a positive
ICAM-1 protocol using tissue that can be fixed on the Cal Poly campus to ensure proper
fixation for use with IHC and immunofluorescence.
On the Santa Cruz Biotechnology website, research articles are listed that use the
same ICAM-1 antibody. Dr. Hsinyu Lee was contacted about the article

56

“Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi- and NF{kappa}B-dependent mechanism Lee” (34) in which immunofluorescence was used. Dr.
Anil Kumar Bhunia was also contacted about his research article "Lactosylceramide
Mediates Tumor Necrosis Factor-induced Intercellular Adhesion Molecule-1 (ICAM-1)
Expression and the Adhesion of Neutrophil in Human Umbilical Vein Endothelial Cells,”
in this article immunofluorescence and IHC was used.
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CHAPTER 3:
SUMMARY AND CONCLUDING REMARKS
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Summary
This project worked towards the goal of creating an ICAM-1 protocol to
be used in creating a “diabetic” environment. In summary, a “diabetic” environment in
which to test stents would be very beneficial. Diabetes is marked by endothelial
dysfunction leading to the upregulation of ICAM-1, procoagulation, inflammation and
decreased vasodilation. ICAM-1 causes leukocytes to migrate into the vessel leading to
an atherosclerotic plaque build up, which can rupture and form a clot, or impede blood
flow. It is widely accepted that diabetic patients react differently to stents than nondiabetic patients; this is thought to be due to inflammation, lesion complexity and
atherosclerosis, all commonly found in diabetic patients (9). With 6% of the population
in the US having diabetes, and a high rate of cardiovascular disease in diabetics, a better
treatment is imperative (16). ICAM-1 is an appropriate marker for diabetes and can be
used to measure if a “diabetic” environment has been created in the BVM. Studies have
shown that elevated plasma levels of ICAM-1 and e-selectin are predictors of diabetes
(38). Once a protocol is created, different methods of ICAM-1 upregulation can be tested
in the BVM to ultimately lead to the end goal of testing stents in the BVM. If ICAM-1
can be upregulated in the BVM and then stents are tested it would be time and cost
effective to be able to characterization the stents in vitro before animal models are used.

Challenges
H&E, immunohistochemistry and immunofluorescence were investigated and
performed as part of this project. Background staining was seen through both IHC and
immunofluorescence; further investigation is required to create a working ICAM-1
59

protocol. The tonsil tissue seemed very sensitive to the hematoxylin and the time in
hematoxylin had to be reduced to 2:30 minutes.
Throughout the attempts of IHC, brown staining was seen in the experimental and
control samples. When hydrogen peroxide was used the expression did not seem to be as
dark. The changing of the time in the peroxidase substrate did not make much of a
difference and the change in the concentration of anti-ICAM-1 antibody did not have
much of an affect either. The addition of heat treatment to unmask the antigen also did
not change the background staining seen.
When the protocol was switched to immunofluorescence, the same problem
persisted. Green fluorescing was seen throughout much of the tonsil tissue. Different
concentrations were attempted. Even at a FITC dilution of 1:1000, fluorescing was still
seen. To attempt to fix this problem, a different secondary antibody was used and there
was still background staining. HUVECs were cultured and used as well, however the
fixation process must be perfected. This process could hold potential, however, the
process of upregulating ICAM-1 is experimental as well. If there is an error in the
process of upregulating ICAM-1 then ICAM-1 would not be expressed. If ICAM-1 is not
expressed, it would not be known, so therefore it would be unknown if the error were in
the protocol of upregulating ICAM-1 or detecting if ICAM-1 is upregulated. The
HUVECs on ePTFE did show a little bit of fluorescing, however, more so when the
hydrophobic barrier pen was used, which was later found to be fluorescent itself.

Future Work
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Future studies could find an alternative to the hydrophobic barrier pen, such
examples include wax from a candle or a crayon. These samples could then be compared
to the tonsil tissue where the hydrophobic barrier pen was used. Another option would be
to try the HUVECs on ePTFE without the hydrophobic barrier pen, however, this would
still require that a positive ICAM-1 source be found. This would be useful to see if the
background staining is only related to the tonsil tissue.
A different source of samples that are positive for ICAM-1 must also be found. It
is likely due to the fixation of the tonsil tissue that is causing the background staining.
Since the tonsil tissue cannot be obtained and fixed on the Cal Poly campus, another
source must be found. It may be possible to find what tissue in mice would express
ICAM-1. This tissue could then be obtained and fixed in histochoice as opposed to
formalin to prevent the background staining.
Cultured cells can also be analyzed further to get a working protocol, if they are
fixed properly they should remain in the well plates. If dextran is used however, it is
uncertain if the protocol of adding dextran, the percent dilution, and incubation time, will
upregulate ICAM-1. So if the protocol is used and no ICAM-1 is seen, it will be
unknown whether it is due to an incorrect protocol or if the HUVECs are not expressing
ICAM-1. Santa Cruz Biotechnology uses Hela cells as a positive control for ICAM-1,
however these cells have been known to be able to take over other cell cultures and could
be risky to use in the hood with other cells.
Also, more researchers who have used the same antibody from Santa Cruz
Biotechnology can be contacted to see if they can provide their working protocol, which
could be mimicked.

61

All of these are issues that can be assessed further to create a working protocol of
ICAM-1 leading to the eventual goal of finding stents with the most potential in treating
diabetic patients.
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